Literature DB >> 2789931

Calcium channel antagonists and cyclosporine metabolism: in vitro studies with human liver microsomes.

J F Tjia1, D J Back, A M Breckenridge.   

Abstract

The effects of four Ca2+ channel antagonists on the metabolism of cyclosporine (CsA) by human liver microsomes (n = 4) in vitro have been examined. Nicardipine produced marked inhibition of both M17 and M21 (IC50 = 7.0 microM) formation. In contrast nifedipine produced less than 20% inhibition of M17 and M21 even at the highest concentration examined (50 microM). Diltiazem data were comparable to those for nifedipine. Verapamil (50 microM) produced 30 and 28% inhibition of M17 and M21 formation, respectively. These findings give a basis to the increase in CsA blood concentrations seen in transplant patients who are also given nicardipine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2789931      PMCID: PMC1379957          DOI: 10.1111/j.1365-2125.1989.tb05439.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine.

Authors:  D J Edwards; R Lavoie; H Beckman; R Blevins; M Rubenfire
Journal:  Clin Pharmacol Ther       Date:  1987-01       Impact factor: 6.875

2.  Cyclosporine A: a clinical evaluation of drug interactions.

Authors:  I Cockburn
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

3.  Influence of diltiazem on cyclosporin clearance.

Authors:  J M Griño; I Sabate; A M Castelao; J Alsina
Journal:  Lancet       Date:  1986-06-14       Impact factor: 79.321

4.  Nicardipine increases cyclosporin blood levels.

Authors:  B Bourbigot; J Guiserix; J Airiau; L Bressollette; J F Morin; J Cledes
Journal:  Lancet       Date:  1986-06-21       Impact factor: 79.321

5.  Liquid-chromatographic determination of cyclosporin A in blood and plasma.

Authors:  R J Sawchuk; L L Cartier
Journal:  Clin Chem       Date:  1981-08       Impact factor: 8.327

6.  In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase.

Authors:  T Inaba; M Jurima; W A Mahon; W Kalow
Journal:  Drug Metab Dispos       Date:  1985 Jul-Aug       Impact factor: 3.922

7.  Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil.

Authors:  K W Renton
Journal:  Biochem Pharmacol       Date:  1985-07-15       Impact factor: 5.858

8.  The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites.

Authors:  H S Purba; J L Maggs; M L Orme; D J Back; B K Park
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of cyclosporin.

Authors:  R J Ptachcinski; R Venkataramanan; G J Burckart
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

10.  The metabolism and pharmacokinetics of nicardipine hydrochloride in man.

Authors:  D J Graham; R J Dow; D J Hall; O F Alexander; E J Mroszczak; D Freedman
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

View more
  11 in total

1.  Proceedings of the British Pharmacological Society, British Pharmacology Section. 18-20 April 1990, Sheffield. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

Review 2.  Pharmacokinetic drug interactions with cyclosporin (Part II).

Authors:  G C Yee; T R McGuire
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

3.  Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics.

Authors:  L M Forrester; C J Henderson; M J Glancey; D J Back; B K Park; S E Ball; N R Kitteringham; A W McLaren; J S Miles; P Skett
Journal:  Biochem J       Date:  1992-01-15       Impact factor: 3.857

Review 4.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

5.  Cyclosporin metabolism by the gastrointestinal mucosa.

Authors:  J F Tjia; I R Webber; D J Back
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 6.  The clinical and economic potential of cyclosporin drug interactions.

Authors:  J E Martin; A J Daoud; T J Schroeder; M R First
Journal:  Pharmacoeconomics       Date:  1999-04       Impact factor: 4.981

7.  Increase in plasma propranolol caused by nicardipine is dependent on the delivery rate of propranolol.

Authors:  I Vercruysse; D L Massart; A G Dupont
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

8.  Cyclosporin metabolism by human gastrointestinal mucosal microsomes.

Authors:  I R Webber; W H Peters; D J Back
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

9.  Influences of the calcium antagonists nicardipine and nifedipine, and the calcium agonist BAY-K-8644, on the pharmacokinetics of propranolol in rats.

Authors:  I Vercruysse; D F Schoors; D L Massart; A G Dupont
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

10.  Intravenous nicardipine in hypertensive children.

Authors:  J M Treluyer; P Hubert; P Jouvet; S Couderc; M Cloup
Journal:  Eur J Pediatr       Date:  1993-09       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.